12:00 AM
 | 
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tamibarotene: Phase IIb discontinued

CytRx discontinued a double-blind, international Phase IIb trial in 140 patients with stage IIIb/IV NSCLC after an interim analysis showed that first-line treatment with twice-daily oral tamibarotene plus paclitaxel and carboplatin was unlikely to meet the primary endpoint of improving PFS vs. placebo plus paclitaxel and carboplatin. CytRx made the decision based on a recommendation from the study's independent DSMB....

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >